- Patients with eosinophilic esophagitis (EoE) suffer from severe symptoms including swallowing disorders, food impaction, vomiting, and heartburn
- EsoCap is currently conducting a randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients in four European countries with its lead candidate ESO-101
- To help raise awareness of the medical condition, EsoCap supports EUREOS and its activities
EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, is supporting the first European EoE day to be launched on 22 May 2022 initiated by EUREOS (European Society of Eosinophilic Oesophagitis) and AEDESEO, the Spanish association of EoE patients. The campaign is the first of its kind in Europe and highlights the need for more public information about eosinophilic esophagitis in general and more specifically, about EoE diagnosis and treatment pathways.
